Samsung (SSNLF) is best known for its smartphones, but its five-year-old drug arm Bioepris is close to receiving its third drug approval.
Bioepis is expected to win final approval for rheumatoid arthritis drug called Imraldi that will be offered at a competitive price to the world's top-selling drug Humira from AbbVie Inc (ABBV) - Get Report , the Wall Street Journal reported. Humira's patent expires in October 2018.
Editors' pick: Originally published June 24.
Don't miss these top stories from TheStreet:
- Could Walmart Shock Everyone By Spending Over $70 Billion to Buy Costco to Take on Amazon? Well...
- 20 Photos Will Help You Get Why Money-Losing Tesla Is Worth More Than $60 Billion
- Travis Kalanick and the Terrible, Horrible, No Good, Very Bad Week
- Alibaba's Jack Ma: China Needs More 'Made in America' Products